Study: Drinking Green Tea, Coffee Lowers Risk of Death for Stroke and Heart Attack Survivors
February 11th 2021In addition, the study found that daily coffee consumption helps heart attack survivors by lowering their risk of death after a heart attack and can help prevent heart attacks or strokes in healthy individuals.
Read More
FDA to Evaluate Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
February 11th 2021A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.
Read More
More Than Half of American Adults with Multiple Sclerosis Report Mistreatment by Caregivers
February 10th 2021Patients with multiple sclerosis who rely on family members as caregivers may be at particular risk for mistreatment, as those caregivers struggle to balance work, childcare, and health concerns of their own.
Read More
FDA Issues EUA for Monoclonal Antibodies as Treatment for COVID-19
February 10th 2021A clinical trial of patients with COVID-19 at high risk for disease progression showed that a single intravenous infusion of bamlanivimab and etesevimab together significantly reduce COVID-19-related hospitalization and death.
Read More
Study: US Adults Report Highest Stress Level Since Early Days of COVID-19 Pandemic
February 9th 2021Moreover, 9 in 10 adults say that they hope the country moves toward unity, according to Stress in America: January 2021 Stress Snapshot, conducted by The Harris Poll on behalf of the American Psychological Association (APA).
Read More
FDA Grants Breakthrough Therapy Designations for Investigational STAMP inhibitor in CML
February 9th 2021The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.
Read More
FDA Approves Breyanzi for Adults with Relapsed, Refractory Large B-cell Lymphoma
February 8th 2021Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.
Read More
Medicaid Expansion Helped Identify Undiagnosed HIV Infections, Increased Prevention Services
February 8th 2021In order to eradicate HIV, the researchers said increasing health coverage will be essential. Without that, HIV will continue to spread, and individuals will be unaware of their status.
Read More